Please provide your email address to receive an email when new articles are posted on . Adult patients with moderate-to-severe ulcerative colitis safely achieved 12-week remission with investigational ...
Response to immune checkpoint inhibitor (ICI) rechallenge in patients with metastatic renal cell carcinoma who progressed on prior ICI: A systematic review and meta-analysis. Biomarkers of response to ...
U.S. FDA Grants Shire Orphan Drug Designation for Investigational Anti-MAdCAM Antibody SHP647 for the Treatment of Moderately to Severely Active Ulcerative Colitis in Pediatric Patients Cambridge, Ma.
Please provide your email address to receive an email when new articles are posted on . An investigational anti-MAdCAM antibody was safe, well tolerated and superior to placebo for inducing remission ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results